Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Research Coverage on Small and Micro-Cap Companies

Equity Bottom-Up

<ul><li>On March 18, 2025, Dogwood Therapeutics, Inc. announced that the first patient was dosed in the Phase 2b HALT-CINP clinical trial of its lead asset, Halneuron .</li><li>The goal is to recruit 100 patients and perform an interim analysis by the fourth quarter of 2025, which will enable changes to the study, if necessary, to improve trial outcomes.</li><li> On March 12, 2025, Dogwood announced a debt conversion with its largest shareholder.</li></ul>

On March 18, 2025, Dogwood Therapeutics, Inc. announced that the first patient was dosed in the Phase 2b HALT-CINP clinical trial of its lead asset, Halneuron .The goal is to recruit 100 patients and perform an interim analysis by the fourth quarter of 2025, which will enable changes to the study, if necessary, to improve trial outcomes. On March 12, 2025, Dogwood announced a debt conversion with its largest shareholder.

DWTX: First Patient Dosed in Phase 2b Trial of Halneuron in CINP  Debt Conversion Strengthens Balance Sheet